William F. Benedict

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

66h-index13.6kcitations213works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(70), Ocular Oncology and Treatments(42), Bladder and Urothelial Cancer Treatments(38), Cancer Research and Treatments(34), Virus-based gene therapy research(26)

Publications213 total

Deglycosylation Does Not Affect the Cytotoxic Action of Adenoviral Interferon α‐Induced Bystander Proteins
The FASEB Journal·2022
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers
Nature Communications·2022· 65 citedOpen Access
Abstract 385: MTAP gene deficiency creates vulnerability to anti-folate therapy in urothelial bladder carcinoma
Cancer Research·2019· 1 cited
Abstract 385: MTAP gene deficiency creates vulnerability to anti-folate therapy in urothelial bladder carcinoma
Experimental and Molecular Therapeutics·2019
A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers
Molecular Therapy·2016· 63 citedOpen Access
Abstract CT059: Systemic administration using targeted gene delivery with SGT-RB94 shows evidence of tumor targeting and anticancer activity: a phase I first-in-man trial
Cancer Research·2016
Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer
Annals of Surgical Oncology·2016· 35 citedOpen Access
72. A Phase l Study of RB94 in Genitourinary Cancers Using a Tumor-Targeted Systemic Nanodelivery System
Molecular Therapy·2016· 1 citedOpen Access
The Use of Ascorbic Acid for Selection of Transformed Cells with Differences in Tumorigenicities and Anchorage-Independent Growth: Implications for Chemoprevention1
2015· 2 cited
Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study
Cancer Gene Therapy·2014· 13 citedOpen Access
Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer
The Journal of Urology·2013· 120 citedOpen Access
Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer
Cell Cycle·2012· 20 citedOpen Access
Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation
Cancer Gene Therapy·2011· 13 cited
Direct gene transfer of adenoviral-mediated interferon α into human bladder cancer cells but not the bystander factors produced induces endoplasmic reticulum stress-related cytotoxicity
Cancer Gene Therapy·2010· 8 citedOpen Access
Autophagy is induced by adenoviral-mediated interferon α treatment in interferon resistant bladder cancer and normal urothelial cells as a cell death protective mechanism but not by the bystander factors produced
Cancer Gene Therapy·2010· 16 citedOpen Access
Abstract 1502: Adenoviral-mediated interferon α induces endoplasmic reticulum stress related cytotoxicity in human cancer but not normal cells
Cancer Research·2010
A phase I study of intravesical Ad-IFN in superficial bladder cancer patients
Journal of Clinical Oncology·2009· 1 cited
PRELIMINARY RESULTS OF A PHASE I STUDY WITH INTRAVESICAL ADMINISTRATION OF ADENOVIRAL-MEDIATED INTERFERON-α FOR PATIENTS WITH BCG REFRACTORY TRANSITIONAL CELL CARCINOMA OF THE BLADDER
The Journal of Urology·2009· 2 cited
Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon α: possible use as a surrogate marker
Cancer Gene Therapy·2009· 14 citedOpen Access
Early RB94-produced cytotoxicity in cancer cells is independent of caspase activation or 50 kb DNA fragmentation
Cancer Gene Therapy·2008· 10 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Hong Xu(8), A. Linn Murphree(7), Shi‐Xue Hu(6), Colin P. Dinney(6), Peter A. Jones(5), Ashutosh Banerjee(4), Bogdan Czerniak(4), Walter E. Laug(4), Shi Xue Hu(4), Rei Takahashi(4), Hao Xu(4), Robert S. Sparkes(3), Susan Groshen(3), Hong‐Ji Xu(3), H. Barton Grossman(3), Shaojun Hu(3), Maryellen C. Sparkes(2), Hideo Tokunaga(2), Jain-Hua Zhou(2), Seth P. Lerner(2)